Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51,946 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J, Wang T, Yang Y, Huang J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Guo Y, Zhou C, Ma K, Fang J, Feng W, Liu Y, Zheng Z, Li G, Wang H, Cang S, Wu N, Song W, Liu X, Zhao S, Ding L, Selvaggi G, Wang Y, Xiao S, Wang Q, Shen Z, Zhou J, Zhou J, Zhang L. Zheng J, et al. Among authors: wang h, wang y, wang t, wang q. Cancer Commun (Lond). 2024 Apr;44(4):455-468. doi: 10.1002/cac2.12524. Epub 2024 Feb 29. Cancer Commun (Lond). 2024. PMID: 38421881 Free PMC article. Clinical Trial.
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study.
Wang T, Zhang P, Di L, Wang X, Yang J, Tong Z, Liu J, Feng J, Liu D, Yu Q, Liu Y, Yu H, Jiang Z. Wang T, et al. Among authors: wang x. Transl Breast Cancer Res. 2022 Apr 30;3:15. doi: 10.21037/tbcr-21-42. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751509 Free PMC article.
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2- metastatic breast cancer.
Yuan Y, Zhang S, Wang T, Wang B, Wang S, Shi J, Sun T, Yin Y, Ouyang Q, Li J, Wen Y, Zhang L, Jiang Z. Yuan Y, et al. Among authors: wang t, wang s, wang b. Transl Breast Cancer Res. 2023 Apr 30;4:10. doi: 10.21037/tbcr-23-9. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751483 Free PMC article.
51,946 results
You have reached the last available page of results. Please see the User Guide for more information.